These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21956617)

  • 1. Commercial factors override science in combination addiction drug trial.
    Byrne A
    Clin Pharmacol Ther; 2011 Nov; 90(5):649; author reply 650. PubMed ID: 21956617
    [No Abstract]   [Full Text] [Related]  

  • 2. Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder.
    Phillips RH; Salzman M; Haroz R; Rafeq R; Mazzarelli AJ; Pelletier-Bui A
    Ann Emerg Med; 2019 Sep; 74(3):430-432. PubMed ID: 30773411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
    Strain EC; Harrison JA; Bigelow GE
    Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid dependence.
    Praveen KT; Law F; O'Shea J; Melichar J
    Am Fam Physician; 2012 Sep; 86(6):565-6. PubMed ID: 23062049
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution and update of detoxification techniques for opiate addicts].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2000 Oct; 20(4):175-7. PubMed ID: 11215403
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.
    D'Amore A; Romano F; Biancolillo V; Lauro G; Armenante C; Pizzirusso A; Del Tufo S; Ruoppolo C; Auriemma F; Cassese F; Oliva P; Amato P
    Clin Drug Investig; 2012 Jul; 32(7):427-32. PubMed ID: 22559256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer from high dose methadone to buprenorphine/naloxone.
    Wallace M
    Aust Nurs J; 2011 Jul; 19(1):42-3. PubMed ID: 21853690
    [No Abstract]   [Full Text] [Related]  

  • 12. Buprenorphine versus methadone use in opiate detoxification, are there other factors that should be considered?
    Bhupal HK
    Br J Gen Pract; 2012 Feb; 62(595):68-9. PubMed ID: 22520768
    [No Abstract]   [Full Text] [Related]  

  • 13. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double successful buprenorphine/naloxone induction to facilitate cardiac transplantation in an iatrogenically opiate-dependent patient.
    Rodgman C; Pletsch G
    J Addict Med; 2012 Jun; 6(2):177-8. PubMed ID: 22456493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacists may dispense new opioid addiction treatment.
    Traynor K
    Am J Health Syst Pharm; 2002 Nov; 59(22):2150, 2152. PubMed ID: 12455298
    [No Abstract]   [Full Text] [Related]  

  • 16. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
    DiPaula BA; Menachery E
    J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine.
    Saleh MI
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3935-42. PubMed ID: 25555887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research.
    Clark N; Verster A
    Addiction; 2013 Feb; 108(2):253-5. PubMed ID: 23331880
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.